Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

摘要: Abstract Purpose One of the hallmarks cancer immunotherapy is long duration responses, evident with cytokines like interleukin-2 or a variety vaccines. However, there limited information available on very term outcomes patients treated anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibodies. Tremelimumab an anti-CTLA-4 antibody immunoglobulin G2 (IgG2) isotype initially tested in advanced melanoma over 12 years ago. Methods We reviewed enrolled four phase 1 and 2 tremelimumab trials at two sites to determine response rates long-term survival. Results A total 143 were institutions from 2002 2008. administration varied between single dose 0.01 mg/kg 15 mg/kg every 3 months. Median overall survival was 13 months (95% confidence interval (CI), 10–16.6), ranging less than month 12+ years. An objective rate 15.6% observed, median 6.5 years, range 3–136+ months. The Kaplan–Meier estimated 5 year 20% CI, 13–26%), 10 12.5 year 16% 9–23%). Conclusions CTLA-4 blockade can lead anti-tumour responses beyond 12 years.